Loading company…
RevolKa develops biopharmaceuticals using AI-based protein engineering.
RevolKa's aiProtein® technology combines artificial intelligence with directed protein evolution to develop engineered proteins. The company is open to research collaborations and co-development. Founded in 2021 and based in Tokyo, Japan, it raised JPY 100 million in Series A funding co-led by Deepcore and D3 LLC in August 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in